Cure My Disease

Don't miss your cure!

 Log in / Sign up

Is RSV a hidden driver of severe COPD attacks?

NCT ID NCT06735612

Knowledge-focused Sponsor: Fundacio Privada Mon Clinic Barcelona Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early This study
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Sep 14, 2026 · Last updated Sep 15, 2026 · Updated 1 time

Summary

Researchers are studying adults with COPD who go to the emergency room or day hospital for sudden worsening of their breathing. The study checks how many of these patients test positive for respiratory syncytial virus (RSV) during the RSV season, from October to April. They compare patients with and without RSV to see if the virus is linked to more hospital admissions, longer stays, heart problems, or death. Participants receive standard COPD care and routine RSV testing; no experimental treatment is given.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If RSV turns out to be a common trigger of COPD flare-ups, doctors could test for it more routinely and consider antiviral or vaccine strategies to protect this group.
What could go wrong
This is an observational study, so it can show patterns but not prove cause and effect. RSV may turn out to be a minor player compared with other triggers, and the findings may not apply to all COPD patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

716 people

The number who actually took part.

Started

Dec 2024

Finished

May 2026

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Patients with the presence of RSV infection (RSV+ considered as cases and RSV- considered as controls) in ECOPD at the Emergency Room or Day Hospital facilities.

Ages

50 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Female or male * ≥50 years of age * Seeking urgent medical attention because of ECOPD, as defined by the Rome consensus definition: "in a patient with COPD, an exacerbation is an event characterized by dyspnea and/or cough and sputum that worsen over \<14 d, which may be accompanied by tachypnoea and/or tachycardia and is often associated with increased local and systemic inflammation caused by airway infection, pollution, or other insult to the airways" Exclusion Criteria: * Previous RSV vaccination (other vaccines will be allowed and recorded) * Active cancer (or any other disease) that may alter the immune status of the patient * Neurologic disorders that incapacitate the participation of the patient * No signing of the informed consent

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Chronic obstructive pulmonary disease (COPD) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

chronic obstructive pulmonary disease COPD, severe early onset respiratory syncytial virus infectious disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Chronic obstructive pulmonary disease (COPD) COPD Exacerbation of COPD Respiratory synctial virus

Contacts and locations

Locations

  • Hospital Clínic de Barcelona

    Barcelona, Spain

More trials for these conditions

Other studies related to the condition(s) this trial covers.